ANI Pharmaceuticals Inc (ANIP)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -22,212 | 19,872 | -62,665 | -56,058 | -25,962 |
| Revenue | US$ in thousands | 614,376 | 486,816 | 316,385 | 216,136 | 208,475 |
| Pretax margin | -3.62% | 4.08% | -19.81% | -25.94% | -12.45% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-22,212K ÷ $614,376K
= -3.62%
ANI Pharmaceuticals Inc's pretax margin experienced fluctuating performance over the past five years. The margin was negative in both 2020 and 2021, indicating that the company's operating expenses and interest payments exceeded its pre-tax income during those periods. However, in 2022, the pretax margin improved slightly but remained negative at -19.81%.
In a positive turn of events, ANI Pharmaceuticals Inc managed to achieve a pretax margin of 4.08% in 2023, marking a significant improvement from the previous years. This positive margin suggests that the company was able to generate pre-tax profits relative to its total revenue after accounting for all relevant expenses.
However, in the most recent period of 2024, the pretax margin declined to -3.62%, albeit still negative. This decrease may indicate challenges in controlling costs or generating sufficient revenue to offset expenses, impacting the company's profitability.
Overall, ANI Pharmaceuticals Inc's pretax margin performance demonstrates a mix of negative and positive trends, indicating a need for continued monitoring and potential strategic adjustments to enhance profitability in the future.
Peer comparison
Dec 31, 2024